Avenue Therapeutics Inc (ATXI)
0.707
+0.04
(+5.37%)
USD |
NASDAQ |
Sep 29, 16:00
0.661
-0.05
(-6.51%)
Pre-Market: 08:22
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.142M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -90.25% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.69% |
Profile
| Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule for CNS diseases, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults. |
| URL | https://www.avenuetx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Florida |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 16, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule for CNS diseases, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults. |
| URL | https://www.avenuetx.com |
| Investor Relations URL | N/A |
| HQ State/Province | Florida |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | N/A |
| Last Earnings Release | Aug. 16, 2021 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |